和并发性精神疾病患者的拉科萨米德单疗法:回顾性图表审查
Ryosuke Mizumura1, Satsuki Watanabe2, Akira Ishikawa1
1Department of Pharmacy, Saitama Medical University Hospital, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.
Epilepsy & behavior : E&B
|July 9, 2025
概括
拉科萨米德 (LCM) 单一治疗有效控制了超过80%的患者的发作,包括患有精神疾病的患者. 这种抗发作药物表现出良好的耐受性,并没有使精神症状恶化.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 经常与抑郁症和焦虑症等精神疾病同时发生,影响患者的生活质量.
- 拉科萨米德 (LCM) 是一种抗发作药物,具有普遍有利的安全性,特别是在患有精神疾病的患者中.
- 对LCM单疗对患有或没有精神病并发症的患者的具体影响需要进一步澄清.
研究的目的:
- 为了评估六个月的lacosamide (LCM) 单一治疗的疗效和耐受性.
- 评估LCM对患有 (PWE) 和没有精神疾病的患者的控制的影响.
- 为了确定LCM单一治疗是否会影响PWE患者的精神症状.
主要方法:
- 在日本中心对55名成人PWE进行了回顾性分析.
- 患者被分为两组:患有精神障碍的人 (n=19) 和没有精神障碍的人 (n=36).
- 在6个月的观察期内评估了发作自由率和精神病学不良影响.
主要成果:
- 在两组中 (有和没有精神疾病) 实现了超过80%的自由度.
- 慢性脑瘤被很好地容忍,只有一个情绪易怒的病例被报告为精神病的不良影响.
- 两名患有焦虑障碍的患者在LCM治疗期间,他们的焦虑症状有所改善.
结论:
- 拉科萨米德单一治疗似乎是PWE的耐受性良好和有效的治疗选择.
- 似乎不会显著恶化精神病症状,甚至可能为一些患有并发症的患者提供好处.
- 这表明LCM是患者的可行选择,包括那些患有并存精神疾病的患者.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
325
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
325
01:20Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
01:26Psychosis: Goals of Pharmacotherapy
213
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
213
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
665
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
665
01:14Antiepileptic Drugs: Glutamate Antagonists
523
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
523
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
456
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
456